On May 21, 2026, the "Global Forum 2026", organized by BioStock, was grandly held in Lund, Sweden. Representatives from leading global life sciences companies and renowned investment funds, including AstraZeneca, Genmab, Insilico Medicine, and EQT, joined industry experts to discuss emerging market prospects, global collaboration opportunities, and industry investment strategies. Aaron Gu of Han Kun Law Offices was invited to attend the event and delivered a keynote speech titled "What You Should Know About the Chinese Life Sciences Market – Highlights, Opportunities and Trends". Drawing on China's rapid development in the global pharmaceutical transaction sector and his extensive practical experience, Mr. Gu shared in-depth insights and unique perspectives on the evolution of China's regulatory framework, the development of transaction models, and emerging trends in the application of clinical data.
During his keynote speech, Mr. Gu systematically reviewed the evolution of China's pharmaceutical regulatory framework and key initiatives since the comprehensive reforms of 2015, including the "722 Storm", the establishment of the MAH system, and the 2024 CGT foreign investment pilot. He also provided an in-depth analysis of structural changes in deal dynamics, such as the shift from license-in to high-value license-out models, the rise of the "NewCo" model, and the accelerating pace of both multinational and domestic M&A, while discussing the advantages and regulatory developments for global companies conducting IITs in China. Finally, Mr. Gu looked ahead to the prospects for Nordic-China cooperation in life sciences sector, noting that China's improving regulatory landscape and vibrant market will unlock broader opportunities for cross-border deals and technical collaboration.
This grand event is hosted by BioStock. As the leading news platform for the life science sector in the Nordic region, BioStock is dedicated to providing real-time industry updates and deep company insights. By combining reliable, industry-wide data with market analysis, BioStock comprehensively empowers the entire life sciences ecosystem.
Aaron Gu's Profile
Mr. Gu specializes in corporate, regulatory compliance, and transactional services for life sciences, biopharmaceutical, medical and healthcare industries, including biosecurity and human genetic resource issues, clinical trial matters, product marketing authorizations, GxP compliance, Spin off-NewCo transactions, drug licensing and collaboration, as well as regulatory issues involved in venture capital and private equity investments, mergers and acquisitions, and foreign and outbound investments in the life sciences industries. Specifically, Mr. Gu's services cover a full range of products including drugs (biologics and chemical drugs), medical devices, IVDs, cosmetics, general foods, special foods (health foods, foods for special medical purposes, and infant formulas), animal drugs, animal foods, etc.
Mr. Gu has extensive experience representing various types of companies in the life sciences industry, including renowned multinational pharmaceutical companies, leading Chinese innovative drug and biotechnology companies, and top domestic and international investment institutions. Mr. Gu has co-authored the China section of Chambers Life Sciences Global Practice Guide (2022-2026) and other publications. His outstanding and professional services have earned him numerous accolades from prestigious institutions such as Chambers and Partners, The Legal 500, China Business Law Journal, Lexpress, LegalOne, Lex Falcon Global Awards, Asian Legal Business (ALB), Legalband and Mondaq. Furthermore, Mr. Gu has been interviewed by 36Kr, Blue View, Caixin, China Business Network, Dutch Financial Daily, Economic Observer, Faxian Magazine, Financial Times, Healthcare Executive, International Pharmaceutical News for China, Jiemian, Southern Weekly, Thomson Reuters and other media (in alphabetical order).
